Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

779P - Prognostic value of micro-vessel density in classical Hodgkin Lymphoma: A systematic review

Date

07 Dec 2024

Session

Poster Display session

Presenters

Devi Amelia

Citation

Annals of Oncology (2024) 35 (suppl_4): S1679-S1697. 10.1016/annonc/annonc1699

Authors

D.A.R. Amelia1, A.M. Lubis2, A. Kurniawan3, C. Sari4, D. Djatnika5, M.A. Nasution1

Author affiliations

  • 1 Internal Medicine, Trainee of Hematology and Medical Oncology Faculty of Medicine Universitas Indonesia, 10430 - Central Jakarta/ID
  • 2 Internal Medicine, University of Indonesia - Faculty of Medicine, 10430 - Central Jakarta/ID
  • 3 Internal Medicine Department, UPH - Pelita Harapan University - Faculty of Medicine, 15810 - Tangerang/ID
  • 4 Internal Medicine Dept., University of Indonesia, 16424 - Depok/ID
  • 5 Haemato-oncology Dept., University of Indonesia, 16424 - Depok/ID

Resources

This content is available to ESMO members and event participants.

Abstract 779P

Background

Angiogenesis plays a role in cancer progression and metastasis. In Hodgkin lymphoma, micro-vessel density (MVD) has been widely used to estimate the degree of angiogenesis. The role of MVD in classical Hodgkin lymphoma is not well defined. The aim of this study is to review prognostic value of MVD in classical Hodgkin lymphoma.

Methods

We searched systematic in several databases for instance PubMed, Science Direct, Google Scholar, Cochrane with relevant keywords related to, classical Hodgkin lymphoma, micro-vessel density, and survival, progression free survival and overall survival. The observational studies last twenty years that reported the association between MVD and survival in classical Hodgkin lymphoma were included. The quality of included study was assessed using Newcastle Ottawa Scale tool.

Results

We included 10 studies with total 968 patients. Five studies were using CD31 as marker for MVD, while the other five were using CD34. There was 6 studies using overall survival as end point. Two studies (402 patients) concluded that MVD negatively correlated with overall survival (OS), while one study with 167 patients concluded that MVD negatively correlated in event free survival (EFS). Three other studies (236 patients) showed no significant correlation between MVD with OS, progression free survival (PFS), relapse and recurrent rate, or disease free survival (DFS). MVD was negatively correlated with stadium, and MVD was shown higher in relapsed refractory HL, however, no correlation between MVD with clinical and pathological profile.

Conclusions

There were conflicting results between studies. However, several studies shown microvascular density associated with worse survival in classical Hodgkin lymphoma. Further multi centre prospective study is needed to see a real association between MVD and survival parameter in classical Hodgkin lymphoma.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.